Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | DNM2 | P50570 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | RXRB | P28702 | 1/20 | 0.31 |
| ▸ | RXRG | P48443 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2536230 | 0.79 | KMT2A (0.65) | KMT2AMEN1KDM4ETSHRNUDT1 | |
| SCHEMBL9977693 | 0.77 | KMT2A (0.57) | KMT2AMEN1KDM4ETSHRNUDT1 | |
| SCHEMBL2789514 | 0.77 | KMT2A (0.47) | KMT2AMEN1KDM4ETSHRNUDT1 | |
| SCHEMBL113085 | 0.77 | — | — | |
| SCHEMBL2757263 | 0.76 | KMT2A (0.61) | KMT2AMEN1TSHRNUDT1SMN1; SMN2 | |
| SCHEMBL1320790 | 0.76 | KMT2A (0.63) | KMT2AMEN1KDM4ENUDT1SMN1; SMN2 | |
| SCHEMBL26601745 | 0.74 | KMT2A (0.48) | KMT2AMEN1KDM4ETSHRNUDT1 | |
| SCHEMBL8168620 | 0.74 | KMT2A (0.44) | KMT2AMEN1KDM4ETSHRJAK2 | |
| SCHEMBL4256097 | 0.73 | NUDT1 (0.42) | KMT2AMEN1TSHRNUDT1TAAR1 | |
| SCHEMBL11190041 | 0.73 | MEN1 (0.42) | KMT2AMEN1TSHRNUDT1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12378254-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2025-08-05 | — | — | US | disclosed |
| US-20240109901-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-C]PYRROLES AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-04 | — | — | US | disclosed |
| US-11667644-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-06 | — | — | US | disclosed |
| US-RE48841-E1 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-07 | — | — | US | disclosed |
| US-20210347781-A1 | Disubstituted Octahydropyrrolo[3,4-c]Pyrroles As Orexin Receptor Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-11 | — | — | US | disclosed |
| US-11059828-B2 | Disubstituted octahydropyrrolo[3,4-C]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-07-13 | — | — | US | disclosed |
| US-20200048263-A1 | Disubstituted Octahydropyrrolo[3,4-C]Pyrroles As Orexin Receptor Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-13 | — | — | US | disclosed |
| EP-2951169-B1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-08-28 | — | — | EP | disclosed |
| EP-3093291-B1 | DISUBSTITUTED OCTAHY - DROPYRROLO [3,4-C]PYRROLES AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-05-08 | — | — | EP | disclosed |
| EP-2300465-B1 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTEX THERAPEUTICS LTD (GB) | 2019-04-17 | — | — | EP | disclosed |
| EP-1838718-B1 | PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | PFIZER (US) | 2011-06-15 | — | — | EP | disclosed |
| WO-2011050202-A1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011050198-A1 | DISUBSTITUTED OCTAHY - DROPYRROLO [3,4-C] PYRROLES AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-28 | — | — | WO | disclosed |
| US-20100222342-A1 | PYRROLOPYRAZOLE, POTENT KINASE INHIBITORS | ZHANG JUNHU | 2010-09-02 | — | — | US | disclosed |
| WO-2010096314-A1 | INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS | AMGEN INC. (US) | 2010-08-26 | — | — | WO | disclosed |
| CN-101693695-A | Pyrimidine derivatives and methods of treatment related to their use | ARENA PHARM INC | 2010-04-14 | — | — | CN | disclosed |
| US-20090036448-A1 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMECUTICAL CO., LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| CN-1976905-A | Pyrimidine derivatives and methods of treatment related to their use | TAISHO PHARMACEUTICAL CO LTD (JP) | 2007-06-06 | — | — | CN | disclosed |
| EP-1730122-A2 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005095357-A2 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109901-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-C]PYRROLES AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OXTR | KMT2A 1722/4885MEN1 3413/4885KDM4E 454/4885 |
| US-12378254-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | HCRTR2, HCRTR1, OXTR | KMT2A 1722/4885MEN1 3413/4885KDM4E 454/4885 |
| US-20210347781-A1 | Disubstituted Octahydropyrrolo[3,4-c]Pyrroles As Orexin Receptor Modulators | HCRTR2, HCRTR1, OXTR | KMT2A 1722/4885MEN1 3413/4885KDM4E 454/4885 |
| US-20200048263-A1 | Disubstituted Octahydropyrrolo[3,4-C]Pyrroles As Orexin Receptor Modulators | HCRTR2, HCRTR1, OXTR | KMT2A 1722/4885MEN1 3413/4885KDM4E 454/4885 |
| US-20100222342-A1 | PYRROLOPYRAZOLE, POTENT KINASE INHIBITORS | PAK4, PAK5, PAK3 | KMT2A 2962/4885MEN1 3121/4885KDM4E 1294/4885 |
| US-11059828-B2 | Disubstituted octahydropyrrolo[3,4-C]pyrroles as orexin receptor modulators | HCRTR2, HCRTR1, OXTR | KMT2A 1722/4885MEN1 3413/4885KDM4E 454/4885 |
| US-20090036448-A1 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | GPR119, HCRTR2, MCHR1 | KMT2A 857/4885MEN1 2494/4885KDM4E 997/4885 |
| US-11667644-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | HCRTR2, HCRTR1, OXTR | KMT2A 1722/4885MEN1 3413/4885KDM4E 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.